ARCSA (Ecuador)

ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria — Dr. Leopoldo Izquieta Pérez) is the Republic of Ecuador's national regulatory authority responsible for the regulation of human medicines + biologicals + vaccines + medical devices + IVDs + processed foods + natural products + cosmetics + hygiene products + biocides + tobacco + sanitary establishments. ARCSA was established by Executive Decree 1290 of 30 August 2012 + the General Health Law (Ley Orgánica de Salud, Law 67 of 2006) as a Public Agency attached to the Ministry of Public Health (MSP — Ministerio de Salud Pública) — the establishment of ARCSA in 2012 consolidated multiple prior regulatory functions previously divided across MSP Directorates + the former Instituto Nacional de Higiene y Medicina Tropical 'Leopoldo Izquieta Pérez' (which dated to 1941 + retains its name as ARCSA's official suffix in honour of the founding hygienist).

ARCSA's organisational structure includes:

• Director Ejecutivo — chief executive appointed by the President; serves at the discretion of the Executive.
• Coordinación General Técnica — technical coordination across product regulation areas.
• Coordinación General Administrativa Financiera — administrative + financial coordination.
• Dirección Técnica de Medicamentos Naturales Procesados de Uso Medicinal — medicines + biologicals + biosimilars + vaccines + natural medicinal products registration.
• Dirección Técnica de Dispositivos Médicos, Reactivos Bioquímicos y de Diagnóstico — medical devices + IVDs + reagents registration.
• Dirección Técnica de Alimentos Procesados y Aditivos Alimentarios — processed foods + food additives registration.
• Dirección Técnica de Productos de Higiene, Cosméticos y Aseo — cosmetics + hygiene + biocides registration.
• Dirección Técnica de Buenas Prácticas y Permisos — Good Practices (GMP, GDP, GCP) inspections + sanitary establishment permits.
• Dirección Técnica de Farmacovigilancia, Tecnovigilancia y Reactivovigilancia — pharmacovigilance + tecnovigilancia + reactivovigilancia + cosmetovigilancia.
• Dirección Técnica de Vigilancia y Control Posterior — post-market surveillance + enforcement + counterfeit-medicine investigation.
• Coordinaciones Zonales — 9 Zonal Coordinations across Ecuadorian provinces executing regional inspections + sanitary establishment authorisations.
• INSPI (Instituto Nacional de Investigación en Salud Pública 'Leopoldo Izquieta Pérez') — separate but coordinated institute providing national reference laboratory services to ARCSA + MSP.

ARCSA is distinct from + complementary to: MSP — Ministerio de Salud Pública (health policy + epidemiology + healthcare service provision); AGROCALIDAD — Agencia Ecuatoriana de Aseguramiento de la Calidad del Agro (veterinary medicines + agricultural inputs + animal-origin foods + plant health); INSPI — Instituto Nacional de Investigación en Salud Pública (national health research institute + reference-laboratory services); MIPRO — Ministerio de Producción, Comercio Exterior, Inversiones y Pesca (industrial policy + trade); SENADI — Servicio Nacional de Derechos Intelectuales (patents + trademarks); SENAE — Servicio Nacional de Aduana del Ecuador (customs interface); + the Colegio Químico Farmacéutico del Ecuador (pharmacist professional body).

Legal foundations are Executive Decree 1290 of 30 August 2012 (establishing ARCSA), Ley Orgánica de Salud (Law 67 of 2006, the General Health Law providing foundational health legislation), Constitución del Ecuador 2008 (Article 363 establishing right to health + State responsibility for health regulation), Reglamento Sustitutivo de Registro Sanitario para Medicamentos en General (current Ecuadorian Pharmaceutical Products Sanitary Registration Regulation), Reglamento para Otorgar Certificaciones de Buenas Prácticas (ARCSA GMP + GDP + GCP Certification Regulation), Resolution ARCSA-DE-026-2016-YMIH (current ARCSA Pharmaceutical Quality framework) + a substantial body of ARCSA technical resolutions.

ARCSA is a WHO/PAHO Member State regulator working toward WHO/PAHO Regional Reference Authority status — ARCSA has been benchmarked against the WHO Global Benchmarking Tool (GBT) + is progressively maturing its regulatory functions. ARCSA is an active WHO Prequalification Collaborative Registration Procedure (CRP) user (accepting WHO-PQ-approved products through accelerated reliance review), a co-leader of the Andean Community (CAN) Pharmaceutical Harmonisation alongside INVIMA Colombia + DIGEMID Peru + AGEMED Bolivia (CAN Decisions 418/516/705/824 are directly applicable under CAN supranational law), an active PANDRH (Pan American Network for Drug Regulatory Harmonisation) participant + a PIC/S Pre-Accession Applicant. Ecuador is also an active participant in ALBA-TCP (Bolivarian Alliance) Health Cooperation including ALBAMED + has historically participated in UNASUR Health Council (when active). ARCSA participates in WHO + PAHO regulatory-strengthening initiatives + leverages PAHO Strategic Fund procurement for essential medicines + vaccines.

Ecuadorian pharmaceutical regulation operates under a layered framework of constitutional provisions + organic laws + executive decrees + Ministerial Agreements + ARCSA Resolutions:

• Constitución del Ecuador 2008 — Article 363 establishing right to health + State responsibility for medicines + medical devices regulation + access to essential medicines.
• Ley Orgánica de Salud (Law 67 of 2006) — foundational General Health Law covering medicines, devices, foods, drugs of abuse + public-health regulation.
• Executive Decree 1290 of 30 August 2012 — establishing ARCSA + consolidating regulatory functions from prior MSP Directorates + INHMT-LIP.
• Reglamento Sustitutivo de Registro Sanitario para Medicamentos en General — current Ecuadorian Pharmaceutical Products Sanitary Registration Regulation.
• Reglamento para Otorgar Certificaciones de Buenas Prácticas — ARCSA GMP + GDP + GCP Certification Regulation.
• Resolution ARCSA-DE-026-2016-YMIH + subsequent resolutions — current Ecuadorian Good Manufacturing Practice framework substantively aligned with WHO TRS 986 Annex 2 + PIC/S GMP Guide + EU GMP + ICH Q7.
• Reglamento de Buenas Prácticas de Distribución — Ecuadorian Good Distribution Practice Regulation substantively aligned with WHO + EU GDP.
• Reglamento para la Aprobación, Realización, Monitoreo y Vigilancia de los Ensayos Clínicos — Ecuadorian Good Clinical Practice + Clinical Trial Regulation substantively aligned with ICH E6(R2).
• Reglamento de Buenas Prácticas de Farmacovigilancia — Ecuadorian Pharmacovigilance Regulation substantively aligned with ICH E2 + EU GVP.
• Reglamento Sustitutivo para Dispositivos Médicos — Ecuadorian Medical Devices Regulation establishing Class I-IV risk classification + Ecuadorian Authorised Representative requirements.
• Reglamento Sanitario de Etiquetado de Alimentos Procesados — Ecuadorian Processed Food Labelling Regulation including the distinctive Ecuadorian semáforo nutricional (traffic-light nutritional labelling) requirement.
• Reglamento Sanitario de Productos Cosméticos — Ecuadorian Cosmetics Regulation substantively aligned with Andean Community Decision 833 + EU Cosmetics Regulation.
• Reglamento Sustitutivo para la Importación y Comercialización de Plaguicidas — Ecuadorian Biocides + Pesticides Regulation (jurisdictional split with AGROCALIDAD).
• Ley Orgánica de Control del Tabaco — Ecuadorian Tobacco Control Law administered by ARCSA + MSP.
• Andean Community Decisions 418/516/705/824 — directly applicable harmonised pharmaceutical framework across Ecuador + Colombia + Peru + Bolivia (legally binding under CAN supranational law).
• Ley Orgánica del Sistema Nacional de Contratación Pública — public procurement law affecting ARCSA-registered products purchased by MSP + IESS (Instituto Ecuatoriano de Seguridad Social).

ARCSA's laboratory functions are operated through INSPI — Instituto Nacional de Investigación en Salud Pública 'Leopoldo Izquieta Pérez' (the Ecuadorian National Institute of Public Health Research) which traces its origins to 1941 + operates Ecuador's National Reference Laboratories. INSPI provides ARCSA's pre-registration quality testing, post-market surveillance testing, lot-release testing for vaccines + biologicals + biological characterisation + counterfeit-medicine forensic analysis. INSPI also operates Ecuador's National Reference Laboratories for public-health analytes including vector-borne diseases (dengue, chikungunya, Zika, malaria — particularly relevant for Ecuador's Amazonian + coastal regions), HIV, tuberculosis, foodborne pathogens, zoonotic diseases + emerging-pathogen surveillance.

• INSPI Pharmaceutical QC — pre-registration + post-market + lot-release testing for medicines, biologicals, vaccines; ISO/IEC 17025 accredited across multiple testing scopes.
• INSPI Reference Laboratories — public-health reference laboratory services across HIV, tuberculosis, malaria, dengue, chikungunya, Zika, leishmaniasis, Chagas disease + emerging-pathogen surveillance.
• WHO PQ-Lab pursuit — INSPI is progressively maturing toward WHO Prequalification of Quality Control Laboratories status; not currently WHO PQ-Lab designated.
• Biological characterisation — INSPI conducts vaccine lot-release testing for ENI procurement + PAHO Revolving Fund-procured vaccines.
• Counterfeit-medicine forensics — INSPI supports ARCSA Dirección Técnica de Vigilancia y Control Posterior investigations of counterfeit + substandard medicines in coordination with SENAE customs + Policía Nacional.
• Public-health toxicology — INSPI operates Ecuador's public-health toxicology service including occupational + environmental toxicology + heavy-metal surveillance (particularly relevant for Ecuadorian mining + petroleum-region populations + Amazonian indigenous populations).
• Tropical-disease reference — INSPI is a PAHO Regional Reference Laboratory for selected tropical diseases reflecting Ecuador's distinctive Amazonian + coastal disease ecology.
• GMP Inspectorate base — ARCSA Dirección Técnica de Buenas Prácticas y Permisos operates GMP inspections of Ecuadorian + foreign manufacturing facilities; ARCSA inspectors progressively maturing toward PIC/S standards through PIC/S Pre-Accession process.
• COVID-19 + pandemic response — INSPI was a central pillar of Ecuador's COVID-19 response including PCR + serology testing, genomic surveillance, vaccine lot release.
• Capacity-building — INSPI hosts training programmes for Andean Community pharmaceutical analysts + contributes to WHO + PAHO + ALBA-TCP regulatory-strengthening initiatives.

ARCSA medical-device + IVD regulation operates under the Reglamento Sustitutivo para Dispositivos Médicos with a Class I-IV risk-based framework substantively aligned with GHTF/IMDRF + EU MDR. Foreign manufacturers must appoint an Ecuadorian Authorised Representative. Processed-food regulation operates under distinctive Ecuadorian frameworks including the semáforo nutricional (traffic-light nutritional labelling) requirement that influenced subsequent Latin American food-labelling reforms.

• Risk-based Classification (Class I / II / III / IV) — substantively aligned with GHTF/IMDRF + EU MDR with Ecuadorian-specific overlay; IVDs classified under separate ARCSA framework.
• Registro Sanitario — issued by ARCSA Dirección Técnica de Dispositivos Médicos based on technical-file review + Ecuadorian Authorised Representative designation + Spanish-language labelling.
• Ecuadorian Authorised Representative — Ecuador-resident legal entity required for foreign manufacturers; bears post-market Tecnovigilancia responsibility + ARCSA regulatory interface.
• ISO 13485:2016 — recognised by ARCSA as QMS evidence framework; Ecuadorian-specific overlay required including Ecuadorian quality records + Representative QMS interface.
• Reliance pathways — ARCSA accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier + accelerates review.
• MDSAP — Ecuador is not currently an MDSAP Participating Regulator + does not require MDSAP audit reports; however ARCSA accepts MDSAP reports as supporting evidence + leverages MDSAP-audited manufacturer evidence in inspection planning.
• Andean Community Medical Device Harmonisation — ARCSA participates in CAN medical-device harmonisation work-streams; reliance + harmonised technical-file requirements progressively expanding across Ecuador + Colombia + Peru + Bolivia.
• Post-market Tecnovigilancia + Reactivovigilancia — ARCSA operates medical-device + IVD-reagent adverse-event reporting through dedicated Ecuadorian Tecnovigilancia + Reactivovigilancia systems; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Processed Food Registration — ARCSA Dirección Técnica de Alimentos Procesados issues Notificación Sanitaria de Alimentos Procesados (NSAP) for processed foods + food additives + dietary supplements; Spanish-language labelling required.
• Semáforo Nutricional — Ecuador's distinctive traffic-light nutritional labelling system requires processed foods to display red/yellow/green nutritional indicators for fat + sugar + salt content based on Ecuadorian Reglamento Sanitario de Etiquetado de Alimentos Procesados; first nationally-mandated traffic-light labelling system in Latin America (introduced 2014) + influenced subsequent Chilean + Peruvian + Mexican octagon-warning labelling reforms.
• Cosmetic Notification — cosmetics under Reglamento Sanitario de Productos Cosméticos + Andean Community Decision 833 require Notificación Sanitaria Obligatoria (NSO) + Spanish-language labelling; INCI-aligned ingredient listing + safety substantiation + cosmetovigilance reporting.
• Hygiene + Biocides — ARCSA Dirección Técnica de Productos de Higiene regulates hygiene products + biocides; jurisdictional split with AGROCALIDAD for agricultural pesticides.
• Ecuadorian UDI — ARCSA is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI; Ecuadorian-specific overlay applies.
• Importation Permit — ARCSA Importation Permit required in addition to product registration for foreign-manufactured devices entering Ecuador via SENAE customs.

ARCSA operates the Sistema Ecuatoriano de Farmacovigilancia under the Reglamento de Buenas Prácticas de Farmacovigilancia. The Ecuadorian pharmacovigilance system integrates national + zonal + hospital + community-pharmacy + manufacturer reporting through ARCSA-managed reporting platforms + leverages WHO PIDM membership since 2007.

• Sistema Ecuatoriano de Farmacovigilancia — coordinated national pharmacovigilance + tecnovigilancia + reactivovigilancia + cosmetovigilancia programme with effector centres at major hospitals + MSP + IESS (Instituto Ecuatoriano de Seguridad Social) + ISSPOL (Police health system) + ISSFA (Armed Forces health system) + Marketing Authorisation Holders.
• WHO PIDM Member — Ecuador is a WHO Programme for International Drug Monitoring member (since 2007) + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC).
• Online ADR Reporting — ARCSA operates online ADR reporting; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — ARCSA accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); ARCSA-specific submission timeline.
• Risk Management Plans (RMP) — ARCSA requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — ARCSA operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + COVID-19 vaccines + biologicals.
• ESAVI (Eventos Supuestamente Atribuibles a Vacunación e Inmunización) — Ecuadorian vaccine adverse-event surveillance system aligned with PAHO ESAVI methodology; central to ENI safety monitoring + PAHO Revolving Fund vaccine surveillance.
• Tecnovigilancia + Reactivovigilancia + Cosmetovigilancia — ARCSA operates parallel materiovigilance for medical devices + IVDs + cosmetics.
• Amazonian + indigenous-population pharmacovigilance — ARCSA + INSPI conduct targeted ADR surveillance in Amazonian + Andean indigenous populations recognising distinctive pharmacokinetic + cultural factors + traditional-medicine interactions.

• WHO Global Benchmarking Tool — ARCSA has been benchmarked against WHO GBT + is progressively maturing toward WHO/PAHO Regional Reference Authority designation; substantial regulatory-strengthening investment ongoing.
• WHO PQ CRP Active User — ARCSA is an active WHO Prequalification Collaborative Registration Procedure (CRP) user accelerating WHO-PQ-approved medicines + vaccines into Ecuador; CRP route substantially reduces review timeline.
• PAHO Revolving Fund — ARCSA coordinates with PAHO Revolving Fund for vaccine + essential-medicine procurement; PAHO-procured products accelerated through ARCSA under PAHO Strategic Fund framework.
• Andean Community Co-Leader — ARCSA is a co-leader of Andean Community (CAN) Pharmaceutical Harmonisation alongside INVIMA Colombia + DIGEMID Peru + AGEMED Bolivia; CAN Decisions 418/516/705/824 are directly applicable under CAN supranational law.
• PANDRH Active Participant — ARCSA is an active PANDRH participant alongside FDA + Health Canada + ANVISA + COFEPRIS + ANMAT + INVIMA + ISP.
• ALBA-TCP Health Cooperation — Ecuador (historical participation, variable per administration) participates in Bolivarian Alliance health cooperation including ALBAMED essential-medicines coordination alongside Venezuela + Cuba + Bolivia + Nicaragua.
• UNASUR Health Council — Ecuador historically participated in UNASUR Council of Health (when active) including ISAGS (Instituto Suramericano de Gobierno en Salud) headquartered in Rio de Janeiro.
• PIC/S Pre-Accession Applicant — ARCSA has commenced PIC/S Pre-Accession process; PIC/S Membership would mark a transformational maturation of Ecuadorian GMP practice + open reliance routes globally.
• ICH Observer — ARCSA engages with ICH guidelines; ICH guidelines extensively implemented in Ecuadorian regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• Bilateral MoUs — ARCSA holds MoUs with FDA + EMA + Health Canada + ANVISA + COFEPRIS + INVIMA + DIGEMID + ANMAT + ISP + AGEMED + Uruguayan MSP + Paraguayan DNVS + Cuban CECMED + Spain AEMPS.
• ICDRA Participant — active International Conference of Drug Regulatory Authorities participant.
• Food Codex Alimentarius — Ecuador active Codex Alimentarius participant; ARCSA + AGROCALIDAD + INEN (Servicio Ecuatoriano de Normalización) coordinate Codex implementation.
• Industry Cooperation — ARCSA engages with ASEDIM (Asociación Ecuatoriana de Distribuidores de Medicamentos), ALAFAR (Asociación de Laboratorios Farmacéuticos Ecuatorianos) + IFI (Industria Farmacéutica Innovadora multinational association).

• Ecuadorian Authorised Representative not properly designated — application rejected at ARCSA intake or post-approval compliance failure.
• Spanish-language labelling deficiencies — Spanish (Ecuadorian variant) labelling + Spanish PIL (prospecto) required; many applicants provide other Latin American Spanish variants without Ecuadorian-specific terminology + climate-appropriate storage conditions.
• GMP Resolution ARCSA-DE-026-2016-YMIH gaps — applicants assuming EU GMP / PIC/S GMP compliance is automatically sufficient without addressing Ecuador-specific ARCSA clarifications + Ecuadorian-specific quality records.
• Ecuadorian climate-zone stability data missing — Ecuador's distinctive geography spans Climate Zone IVa (hot humid coastal + Amazonian regions), Climate Zone II (temperate Andean highlands), Climate Zone IVb (very hot humid Galápagos + lowland Amazonas) + Climate Zone I (cold high-altitude Andean peaks above 3,500m); many applicants provide insufficient zonal-specific stability data + ignore equatorial UV-radiation considerations.
• Andean Community CAN reliance not leveraged — CAN Decisions 418/516/705/824 directly-applicable harmonised framework underutilised by applicants targeting multiple CAN markets through ARCSA + INVIMA + DIGEMID + AGEMED coordination.
• Pacific Alliance not applicable — Ecuador is not a Pacific Alliance Member (Ecuador is CAN-only); applicants must distinguish CAN (Ecuador, Colombia, Peru, Bolivia) from Pacific Alliance (Chile, Colombia, Mexico, Peru) — Colombia + Peru are members of both, Ecuador only of CAN.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated ARCSA CRP review; ARCSA is an active CRP user.
• PAHO Revolving Fund route not leveraged — PAHO Strategic Fund + Revolving Fund procurement provides registration acceleration + reduced documentation burden for essential medicines + vaccines.
• AGROCALIDAD jurisdictional split — veterinary medicines + agricultural inputs + animal-origin foods + plant health sit with AGROCALIDAD, not ARCSA; avoid filing veterinary or animal-origin food applications to ARCSA.
• Semáforo nutricional non-compliance — Ecuador's distinctive traffic-light nutritional labelling for processed foods catches many international food manufacturers unprepared; semáforo requirements are specific to Ecuador + must be addressed at packaging design stage.
• INSPI coordination required — laboratory analyses are conducted by INSPI rather than ARCSA in-house; coordination + sample submission procedures specific to INSPI framework.
• Zonal Coordinations regional scope — sanitary establishment permits + pharmacy licensing + healthcare-facility licensing executed by ARCSA Zonal Coordinations across 9 Coordinations; regional procedural variation exists.
• Vital-need pathway not leveraged — MSP + ARCSA vital-need + orphan pathway underutilised; provides regulatory acceleration + MSP + IESS coverage acceleration for eligible products.
• Variations strategy not planned — variations procedure substantively similar to WHO but with Ecuador-specific timelines + fee structure + Spanish-language requirements.
• Renewal timing missed — 5-year Registro Sanitario renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial Reglamento de Ensayos Clínicos + REC steps — Ecuadorian clinical trials require ARCSA CTA + INSPI-recognised Research Ethics Committee approval; sponsors sometimes overlook indigenous-community consent for Amazonian + Andean populations under Ecuadorian Constitution 2008 Article 57 (collective rights of indigenous peoples) obligations.

V5 Ultimate provides the operational infrastructure Ecuadorian + foreign-supplier sites need for Executive Decree 1290 of 2012 + Ley Orgánica de Salud + Reglamento Sustitutivo de Registro Sanitario + ARCSA Resolution-DE-026-2016-YMIH GMP + ARCSA Medical Devices framework + Andean Community + WHO PQ CRP + ALBA-TCP + Sistema Ecuatoriano de Farmacovigilancia + semáforo nutricional + vital-need pathway readiness.

• ARCSA GMP control framework — WHO TRS 986 Annex 2 + PIC/S + EU GMP + ICH Q7-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Ecuador-specific clarifications + Ecuadorian climate-zone IVa/II/IVb/I stability monitoring + equatorial UV-radiation considerations.
• ARCSA drug-registration packaging — Ecuadorian CTD-aligned dossier structure with Ecuador Module 1 specifics + Module 3 stability + Ecuadorian prospecto + Spanish (Ecuadorian variant) labelling + Authorised Representative declarations + Reglamento Sustitutivo framework + bioequivalence evidence under phased framework.
• Andean Community workflow — CAN Decisions 418/516/705/824 directly-applicable packaging for joint registration across Ecuador + Colombia + Peru + Bolivia; ARCSA + INVIMA + DIGEMID + AGEMED coordination.
• PANDRH workflow — PANDRH reliance pathway packaging for products assessed by FDA + Health Canada + ANVISA + COFEPRIS + ANMAT + INVIMA + ISP Reference Authorities.
• WHO PQ CRP workflow — applicant-side WHO PQ CRP packaging with reduced dossier + accelerated ARCSA review.
• PAHO Revolving Fund workflow — PAHO Strategic Fund + Revolving Fund essential medicine + vaccine procurement packaging with accelerated ARCSA coordination.
• ALBA-TCP / ALBAMED workflow — Bolivarian Alliance health cooperation + ALBAMED essential-medicine procurement packaging (subject to current Ecuadorian Government participation).
• Vital-need + orphan workflow — MSP + ARCSA vital-need + orphan pathway packaging with MSP + IESS coverage acceleration.
• Natural Medicinal Products workflow — Ecuador-distinctive Productos Naturales Procesados de Uso Medicinal registration packaging recognising traditional Andean + Amazonian medicine + biodiversity + traditional-knowledge contributions.
• Ecuadorian Authorised Representative workflow — foreign-manufacturer Representative designation + role-management + Ecuador-specific post-market surveillance + ARCSA interface.
• Ecuadorian clinical-trial workflow — Reglamento de Ensayos Clínicos GCP + INSPI-recognised REC + Ecuadorian SUSAR reporting + indigenous-community consent under Constitution 2008 Article 57.
• ARCSA Pharmacovigilance integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Spanish-language ICSR + Sistema Ecuatoriano de Farmacovigilancia coordination + VigiBase upload + Risk Management Plan packaging + ESAVI vaccine adverse-event reporting.
• Tecnovigilancia + Reactivovigilancia + Cosmetovigilancia workflow — parallel materiovigilance + IVD-vigilance + cosmetovigilance packaging.
• Medical-device + IVD + cosmetic workflow — Reglamento Sustitutivo para Dispositivos Médicos + Reglamento Sanitario de Productos Cosméticos + CAN Decision 833 dossier packaging + Class I-IV classification + ISO 13485 + Ecuadorian Authorised Representative + post-market Tecnovigilancia.
• Semáforo nutricional workflow — Ecuador-distinctive processed-food traffic-light nutritional labelling packaging for fat + sugar + salt indicators per Reglamento Sanitario de Etiquetado de Alimentos Procesados.
• ARCSA Variations workflow — variations classification + ARCSA procedure + Ecuadorian packaging.
• Renewal workflow — 5-year Registro Sanitario renewal window tracking + ARCSA procedure packaging.
• Andean regional bridging — for companies operating across Andean Community, V5 surfaces ARCSA + INVIMA + DIGEMID + AGEMED harmonised dossier-element reuse alongside national-specific extensions.